News | Pharmaceuticals | June 14, 2019

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat

Firibastat is brain aminopeptidase A inhibitor being developed for treatment of resistant hypertension and heart failure

Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat

June 14, 2019 — Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical candidate, firibastat, in patients with heart failure after acute myocardial infarction (AMI). Firibastat is a first-in-class brain aminopeptidase A inhibitor, being developed for the treatment of resistant hypertension and heart failure.

Gilles Montalescot, M.D., Ph.D., lead investigator of the QUORUM trial, commented, “Despite some medical breakthroughs in healthcare throughout the last decade, mortality rate due to heart failure remains high, with about 50 percent of patients diagnosed dying within five years. The initiation of this trial is an important step forward in potentially providing the millions of patients who suffer from heart failure a novel therapy to address their significant unmet needs.”

QUORUM (QUantum Genomics QCG001 Or Ramipril after acUte Myocardial infarction to prevent left ventricular dysfunction) is a multi-center, multinational, randomized, double-blind, active-controlled trial with three parallel groups (firibastat 100 mg BID, firibastat 500 mg BID and ramipril 5 mg BID). The study will enroll 294 subjects within 72 hours after AMI who have been treated with primary percutaneous coronary intervention (PCI). The aim of the study is to assess the efficacy and the safety of firibastat compared to ramipril.

The primary endpoint will be the change from baseline in left ventricle ejection fraction (LVEF) assessed by cardiac magnetic resonance (CMR) after a three-month treatment. Other endpoints will include cardiac events, functional status, safety and change in HF biomarkers.

For more information: www.quantum-genomics.com


Related Content

News | Cardiovascular Clinical Studies

September 8, 2022 — A clinical trial led by investigators from Brigham and Women’s Hospital has found that the long-term ...

Home September 08, 2022
Home
News | Cardiovascular Clinical Studies

August 17, 2022 — A study carried out by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) ...

Home August 17, 2022
Home
News | Cardiovascular Clinical Studies

August 12, 2022 — Older adults with atrial cardiopathy (a major, often undetected cardiac cause of stroke) may be at ...

Home August 12, 2022
Home
News | Cardiovascular Clinical Studies

August 8, 2022 — Two years ago, University of Alabama at Birmingham researchers and colleagues reported that reductive ...

Home August 08, 2022
Home
News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
Subscribe Now